( Epub 2021 Aug 17 PMID: 34403495 ) Vallatharasu Y, Hayashi-Tanner Y, Polewski PJ, Bottner WA, Rosenstein LJ, Uprety D, Bista A, Farnen JP, Aster R (2019) Severe, prolonged thrombocytopenia in a patient sensitive to exenatide
Insurance barriers: While some insurance plans cover GLP-1 therapies, navigating the processes of step therapy and prior authorization can be overwhelming for patients
,aspect=ignore)
Disclosures: Phuc Le: Nothing to Disclose, William Herman: Merck Sharp & Dohme: Advisor, Rivus Pharmaceuticals: Advisor, Srinivasan Dasarathy: Nothing to Disclose, Wen Ye: Nothing to Disclose, Victoria Criswell: Nothing to Disclose, Nicole Welch: Nothing to Disclose, Michael Rothberg: Moderna: Stock - publicly traded company 1763 CLINICAL OUTCOMES OF UTILIZING AN INTERACTIVE CARE PLAN (ICP) IN PATIENTS WITH CIRRHOSIS Kathryn Schmidt 1 Jessica Grimm 1 Devin Copley 1 Daniel Penrice 1 Barbara Copeland 1 William Harmsen 1 Rachel Gullerud 1 Winnie Fan 1 Jordan Coffey 1 Julianne Lunde 1 Sarah Harper 1 Hugo Vargas 2 Blanca Lizaola-Mayo 2 Douglas Simonetto 1 , 1 Mayo Clinic Rochester, 2 Mayo Clinic Arizona Background: Patients with cirrhosis face an increased risk of disease-related symptoms and complications, leading to reduced quality of life

The medication biologically suppresses patients desire to eat, but that doesnt mean it suppresses their need to eat. And although protein, the macronutrient de jour, is a critical element for people taking GLP-1s, its not the be-all end-all
Use the telehealth platform to report any changes in bowel habits or abdominal pain immediately
GLP-1 receptor agonists mimic this hormone to slow digestion, reduce hunger, and keep you feeling full longeran ideal setup for weight loss